Latest Developments in Global Automated Insulin Delivery Devices Market

Request for TOC Request for TOC Speak to Analyst Speak to Analyst Buy Now Buy Now Inquire Before Buying Inquire Before Free Sample Report Free Sample Report

Latest Developments in Global Automated Insulin Delivery Devices Market

  • Healthcare
  • Upcoming Report
  • Nov 2024
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

  • In August 2023, Novo Nordisk A/S reached an agreement to acquire Inversago Pharma for up to USD 1.075 billion, contingent upon meeting specific development and commercial milestones. Inversago, based in Montreal, focuses on therapies targeting the CB1 receptor, with the aim of treating obesity, diabetes, and related metabolic disorders
  • In March 2023, Sanofi announced a significant 78% reduction in the list price of Lantus (insulin glargine injection) 100 Units/mL in the U.S. In addition, the company introduced a USD 35 cap on out-of-pocket costs for patients with commercial insurance, reaffirming its commitment to providing affordable access to essential medicines
  • In March 2023, Diabeloop entered into a partnership with Novo Nordisk to integrate its self-learning algorithm, DBL-4pen, with Novo Nordisk's reusable insulin pens, NovoPen 6 and NovoPen Echo Plus. In doing so, this collaboration aims to improve Multiple Daily Injections (MDI) therapy for Type 2 diabetes patients, with a clinical study planned to assess its effectiveness
  • In November 2022, Novo Nordisk and Abbott formed a partnership to improve diabetes management by making Novo Nordisk’s connected insulin pens compatible with the Abbott FreeStyle LibreLink app. In this way, this integration enables users to sync insulin dosages with glucose levels, offering a comprehensive view for optimized diabetes care
  • In January 2022, Insulet Corp., based in Boston, announced that the FDA had cleared its new Omnipod 5 system, marking the company’s entry into the automated insulin delivery (AID) market

Frequently Asked Questions

The market is segmented based on Segmentation, By Type (Pens, Insulin Pumps, Pen Needles, Insulin Syringes, and Others), End-User (Homecare, Hospitals, and Clinics) – Industry Trends and Forecast to 2031 .
The Global Automated Insulin Delivery Devices Market size was valued at USD 3.29 USD Billion in 2024.
The Global Automated Insulin Delivery Devices Market is projected to grow at a CAGR of 11.43% during the forecast period of 2025 to 2032.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.